These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Khambhati J; Engels M; Allard-Ratick M; Sandesara PB; Quyyumi AA; Sperling L Atherosclerosis; 2018 Sep; 276():1-9. PubMed ID: 30006321 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Murray EC; Nosalski R; MacRitchie N; Tomaszewski M; Maffia P; Harrison DG; Guzik TJ Cardiovasc Res; 2021 Nov; 117(13):2589-2609. PubMed ID: 34698811 [TBL] [Abstract][Full Text] [Related]
26. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Ridker PM Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102 [No Abstract] [Full Text] [Related]
27. Clinical value of drugs targeting inflammation for the management of coronary artery disease. Duchatelle V; Kritikou EA; Tardif JC Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034 [TBL] [Abstract][Full Text] [Related]
29. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Koenig W Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367 [TBL] [Abstract][Full Text] [Related]
30. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. Hafiane A; Daskalopoulou SS Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900 [TBL] [Abstract][Full Text] [Related]
31. Editorial: update on inflammatory targets modulating atherogenesis. Carbone F; Mach F; Montecucco F Curr Drug Targets; 2015; 16(4):282-3. PubMed ID: 25859799 [No Abstract] [Full Text] [Related]
32. Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. Panahi M; Papanikolaou A; Torabi A; Zhang JG; Khan H; Vazir A; Hasham MG; Cleland JGF; Rosenthal NA; Harding SE; Sattler S Cardiovasc Res; 2018 Sep; 114(11):1445-1461. PubMed ID: 30010800 [TBL] [Abstract][Full Text] [Related]
33. Interplay between inflammation and thrombosis in cardiovascular pathology. Stark K; Massberg S Nat Rev Cardiol; 2021 Sep; 18(9):666-682. PubMed ID: 33958774 [TBL] [Abstract][Full Text] [Related]
34. [Cardiovascular risks of corticosteroids]. Szwebel TA; Le Jeunne C Presse Med; 2012 Apr; 41(4):384-92. PubMed ID: 22361027 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular and oral disease interactions: what is the evidence? Ford PJ; Yamazaki K; Seymour GJ Prim Dent Care; 2007 Apr; 14(2):59-66. PubMed ID: 17462139 [TBL] [Abstract][Full Text] [Related]
36. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
37. Therapies targeting innate immunity for fighting inflammation in atherosclerosis. Mendel I; Yacov N; Harats D; Breitbart E Curr Pharm Des; 2015; 21(9):1185-95. PubMed ID: 25312734 [TBL] [Abstract][Full Text] [Related]
38. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Muhlestein JB Thromb Haemost; 2010 Jan; 103(1):71-82. PubMed ID: 20062914 [TBL] [Abstract][Full Text] [Related]
39. Novel anti-inflammatory strategies in atherosclerosis. van der Valk FM; van Wijk DF; Stroes ES Curr Opin Lipidol; 2012 Dec; 23(6):532-9. PubMed ID: 23160400 [TBL] [Abstract][Full Text] [Related]